NEW YORK (GenomeWeb News) – Spanish biotechnology holding company Genetrix today announced it has licensed its Qualiphi polymerase product to Qiagen.
The global, exclusive deal was reached through Genetrix's X-Pol subsidiary.
Qualiphi is a DNA polymerase licensed from the Spanish National Research Council and studies suggest that it may improve the amplifications of whole genomes and large stretches of DNA, Genetrix said.
Financial and other terms of the deal were not disclosed.
Founded in 2011, Genetrix serves as an incubator for Spanish biotech companies established in academic settings. It has invested more than €36 million ($44.2 million) in nine companies with a focus on healthcare technologies, human therapies, and diagnostics.
X-Pol was created by Genetrix and Luis Blanco in 2008 and develops technologies for DNA amplification and sequencing. Genetrix owns 84 percent of the company.